# Retatrutide: The Largest Number, and the Emptiest Withdrawal File > Retatrutide: Research Overview — Metabolic & Weight Research Peptides — Brand My Peptides — A reference-desk entry on retatrutide (LY3437943) among Metabolic & Weight research peptides: the largest Phase 2 weight figure in the class, the structural basis of triple agonism, and the reason its discontinuation record is currently empty. **03 / METABOLIC & WEIGHT RESEARCH** An investigational triple agonist at the GIP, GLP-1 and glucagon receptors. Phase 2 produced the biggest weight figure on this desk; no published trial has yet reported what happens when it stops. ## The short version Retatrutide is an experimental compound that switches on three gut- and pancreas-hormone receptors at once: GIP, GLP-1 and glucagon. The first two lower appetite in the way the other compounds on this desk do. The third is the unusual one — a controlled glucagon signal that appears to raise energy output and mobilise fat, which is a second lever rather than a stronger version of the first. A mid-stage trial reported the largest average weight reduction among the compounds on this desk [15]. That result is often repeated without two essential qualifiers: it comes from Phase 2 rather than a completed pivotal programme, and it was measured while treatment was still being given. Retatrutide is approved by no regulator. It has no published withdrawal arm and no off-treatment follow-up, so what happens after stopping is, for this compound specifically, unmeasured. Nothing on this page is advice, and no quantity described here is a recommendation for any person. ## What it is Retatrutide, also written LY3437943, is a synthetic peptide built on a GIP-based backbone and acylated with a fatty diacid for albumin binding and extended exposure. In the literature it appears as the GGG tri-agonist or, descriptively, as a GIP/GLP-1/glucagon receptor triagonist. A review in the source set describes the molecule's triple-agonist pharmacology and the continuing pivotal programme [12]. Its regulatory position is the single most important fact about it and the one most often left out of summaries. Retatrutide is investigational and is not approved by the FDA or by another regulator in the composed record. There is no approved indication, formulation or labelled dosing; every figure on this page comes from a clinical trial rather than approved labelling, and every participant who generated those figures was inside a monitored trial. GIP, GLP-1 and glucagon receptor agonists are not specifically named on the current anti-doping prohibited list, though the status of an investigational agent is exactly the kind of thing that changes between list revisions. ## How it works One molecule, three receptors. The GLP-1 and GIP arms suppress appetite and improve glucose-dependent insulin secretion, in the manner already familiar from the other two entries on this desk. The glucagon-receptor arm is the addition, and it works in what looks at first like the wrong direction — glucagon raises blood glucose — but in this context contributes energy expenditure and lipid mobilisation. The combination is what produced larger weight reductions in trials than dual or single agonism. The structural work is unusually informative about how that balance is struck. Cryo-electron-microscopy structures show retatrutide engaging all three receptors, and the potencies are deliberately unequal: roughly 8.9-fold more potent at the GIP receptor than native GIP, but only 0.3-fold and 0.4-fold as potent as the endogenous hormones at the glucagon and GLP-1 receptors respectively [13]. What that describes is a restrained glucagon signal riding alongside strong incretin signalling — enough glucagon agonism to add expenditure, not enough to undo the glycaemic work of the other two arms. For the cessation question the addition of a third receptor changes nothing structural. Three occupied receptors are still occupied receptors, and the published pharmacology describes no mechanism by which appetite regulation or energy expenditure would be reset to a new baseline that persists after the molecule clears. ## What the research shows **Weight.** In a 48-week Phase 2 obesity trial, once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% against -2.1% with placebo [15]. A 2025 review synthesising the triple-agonist pharmacology with the Phase 1 and Phase 2 data characterises weight loss of up to roughly 24% as a step-change against prior incretin therapies [12]. **Glycaemia.** In a 36-week Phase 2 trial in type 2 diabetes, retatrutide 12 mg lowered HbA1c by 2.02 percentage points at 24 weeks and reduced body weight by 16.94% at 36 weeks against placebo [16]. **Liver.** In a 48-week Phase 2 substudy in obesity with metabolic dysfunction-associated steatotic liver disease, retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks, with 86% of participants reaching normal liver fat, defined as under 5% [14]. **Structure.** The cryo-EM work confirming engagement at all three receptors, with the asymmetric potencies described above [13]. The evidence has a distinctive shape. It is deep on mechanism — the structural biology is more completely worked out than for either approved comparator at the equivalent stage — and shallow on duration. Every efficacy figure comes from a Phase 2 trial of 36 or 48 weeks. No Phase 3 result has been published, no cardiovascular or renal outcome trial has reported, and no arm has been followed after treatment stopped. ## Reported effects, cautions & safety The block below is **anecdotal, not clinical evidence**. It is drawn from research-community discussion of an unapproved investigational compound obtained outside any trial, is entirely unverified, carries no clinical adjudication and no doses, and describes a setting in which nobody knows what was actually in the vial. *Frequently reported.* Near-total silencing of intrusive food thought — described as disinterest in eating rather than as feeling full — and weight reduction that reporters describe as qualitatively faster than their experience of other compounds in the class. Nausea after administration is the most common adverse description, especially early and after escalation. *Commonly reported:* a sensation of running warm, sometimes described as mild flushing or sweating more easily, which community discussion attributes to the glucagon arm; awareness of a faster resting pulse; low energy or heavy-limbed tiredness in the early phase; sulfur-smelling burps; and constipation. *Occasionally reported:* short-lived localised itching at the injection site; difficulty falling or staying asleep; a lift in mood and reduced anxiety around food; and, from reporters who track body composition, a sense that rapid loss feels soft, which mirrors a genuine open research question rather than settling it. **The documented cautions come from the trial record and from the compound's regulatory position.** - **It is unapproved and investigational.** Material obtained outside a clinical trial has no verified identity, purity or sterility. A grey market exists for research-labelled material; it sits outside clinical oversight entirely, and the compound's own corpus of evidence says nothing about what is in it. - **Dose-dependent gastrointestinal events.** Nausea, vomiting, diarrhoea and constipation were the most common reason for discontinuation in Phase 2. In the 48-week obesity trial nausea affected up to 45% of participants at the highest dose and was the principal driver of the 18% discontinuation rate at that dose level [15]. These arise from GLP-1-mediated slowing of gastric emptying and altered motility. In unmonitored settings there is no escalation oversight, which the literature notes as increasing the likelihood of severe gastrointestinal events, dehydration and electrolyte disturbance. - **Dose-dependent increase in resting heart rate.** Observed in the Phase 2 obesity trial and peaking around 24 weeks [15]. Long-term cardiovascular implications are still being studied, and pre-existing arrhythmia, tachycardia or cardiovascular disease is the context in which that signal matters most. - **Hypoglycaemia in combination.** Risk rises substantially alongside insulin or a sulfonylurea; trial conduct managed this with glucose monitoring and adjustment of background therapy. - **Lean-mass reduction.** Phase 2 body-composition data show absolute reductions in lean mass alongside fat mass. Research attention has turned to whether protein intake and resistance training modify that fraction, which is an open question rather than a settled protocol. - **Long-term safety and durability are unknown.** The review describes the pivotal programme as ongoing [12]. No long-term outcome data exist in the composed record, and durability after discontinuation is named among the gaps. ## Where it sits in the discontinuation record Retatrutide's position in this theme is defined by an absence, and the absence is worth stating precisely rather than filling in. **There is no withdrawal arm.** No published retatrutide trial has randomised participants to continue or to stop, and no published extension has followed participants after treatment ended. The compound's own record contains no observation of what its weight curve does off treatment. The evidence summaries say so directly: durability of weight loss after discontinuation is listed among the explicit unknowns, alongside long-term safety and cardiovascular and renal outcomes, with the pivotal trials still running. **What is being inferred, and by whom.** The published literature on related incretin agents indicates substantial regain after discontinuation, and that is the basis on which retatrutide's own evidence summaries flag rebound as a likely rather than a demonstrated property. This is a mechanistic inference from a class, not a measurement of a compound. It is a reasonable inference — the receptors, the occupancy logic and the albumin-bound weekly pharmacology are all shared — but a reader who wants to know how far it reaches should note that retatrutide's glucagon arm is the one component of its mechanism with no counterpart in the compounds that have been withdrawn and measured. **Why the largest number is the most fragile one.** The -24.2% figure at 48 weeks [15] is the number that travels, and it carries two qualifiers that get stripped in transit. It is a Phase 2 result, which is a stage at which effect sizes are estimated in selected populations and not yet confirmed. And it is an on-treatment result at week 48, which means it describes a state under continuing exposure and says nothing about week 60 with no exposure at all. The heart-rate signal peaking around 24 weeks [15] is a reminder of the same thing from the safety side: the trials were still characterising what the compound does while it is being given. **What this desk will not do.** It will not turn a class inference into a retatrutide figure, will not quote a regain percentage for a compound that has not had one measured, and will not describe how anyone might start, continue or stop anything. Retatrutide is available legitimately only inside a clinical trial, and that is where questions about its administration belong. --- Brand My Peptides is a reference desk on the metabolic-peptide literature: it records what each trial measured, at what point in the trial, and what the withdrawal arms recorded afterwards — it brands nothing, sells nothing, prescribes nothing and advises no one.